CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Net loss	$ (107,956)	$ (2,069,876)	$ (1,554,028)	$ (19,481,526)
Adjustments to reconcile net income to cash used in operating activities, net of acquisitions
Stock based compensation expense			392,413	305,153
Depreciation and amortization			6,059,994	4,716,177
Rent paid by common stock			244,000	0
Gain on sale of assets	0	0	(9,748,561)	0
Loss on sale of assets			115,527	63,410
Increase in fair value of derivative liability	(1,065,217)	(818,051)	(724,185)	(2,635,033)
Deferred federal income tax expense			0	5,306,000	$ 5,306,000
Changes in operating assets and liabilities
Accounts receivable			(62,325)	1,879,150
Allowance for doubtful accounts			0	2,810,146
Business interruption insurance proceeds receivable			(1,275,000)	0
Inventory			(122,924)	8,773,459
Prepaid expenses			(1,530,380)	(924,216)
Costs in excess of billings			0	779,285
Accounts payable and accrued expenses			(4,940,852)	(8,858,058)
Deferred revenue			(248,624)	(495,965)
Other assets			2	0
Net cash used in operating activities			(13,394,947)	(7,762,018)
Cash flows from investing activities
Acquisitions			0	(1,082,649)
Purchase of fixed assets			(3,428,396)	(1,159,488)
Casualty insurance proceeds			2,332,854	0
Proceeds from asset sales			29,788,114	4,500
Costs related to sale of Bango assets			(10,792,446)	0
Establish escrow account - restricted cash			(1,503,228)	0
Notes receivable			0	(500,000)
Proceeds from asset sales			20,900	0
Net cash provided by (used in) investing activities			16,417,798	(2,737,637)
Cash flows from financing activities
Proceeds from sale of Series C Preferred Stock			4,000,000	0
Purchase/Buy Back/Sale Series B Preferred Stock			(11,189,849)	0
Proceeds from issuance of Series B Preferred Stock			(607,890)	0
Proceeds from note payable			7,544,680	2,305,277
Payments on note payable			(19,260,455)	(18,019,983)
Line of credit (payments) proceeds, net			128,662	659,893
Net cash provided by (used in) financing activities			(35,096)	8,502,740
Net change in cash and cash equivalents			2,987,755	(1,996,915)
Cash and cash equivalents at beginning of the period			765,364	6,017,076	6,017,076
Cash and cash equivalents at end of period	3,753,119	4,020,161	3,753,119	4,020,161	765,364
SUPPLEMENTAL INFORMATION
Cash paid for interest			1,431,352	2,835,681
Cash paid (received) for income tax expense (benefit)			117,646	0
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Accretion of discount on Series B and B-1 Preferred Stock	(435,134)	(444,899)	(1,293,669)	(444,899)
Dividends-in-Kind accrued on Series B and B-1 Preferred Stock and retirement of a portion of the Series B Preferred Stock	(6,695,506)	$ (401,951)	(6,695,506)	(401,951)
Beneficial conversion feature for Series B and B-1 Preferred Stock			3,691,683	5,737,796
Fair value of warrants issued with Series B and B-1 Preferred Stock			2,867,264	7,028,067
Series B Preferred Stock
Cash flows from financing activities
Proceeds from issuance of preferred stock			0	23,557,553
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Dividends-in-Kind accrued on Series B and B-1 Preferred Stock and retirement of a portion of the Series B Preferred Stock	(214,227)		(214,227)		$ (376,571)
Series B1 Preferred Stock
Cash flows from financing activities
Proceeds from issuance of preferred stock			19,349,756	0
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Dividends-in-Kind accrued on Series B and B-1 Preferred Stock and retirement of a portion of the Series B Preferred Stock	$ (290,247)		(290,247)
Common stock
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Conversion of Series A Preferred Stock into common stock			$ 120	$ 17